A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner, Es; Keane, Fk; Lindner, R; Tassi, Renata Alessandra; Paranjape, T; Glasgow, M; Nallur, S; Deng, Y; Lu, L; Steele, L; Sand, S; Muller, Ru; Bignotti, Eliana; Bellone, Stefania; Boeke, M; Yao, X; Pecorelli, Sergio; Ravaggi, Antonella; Katsaros, D; Zelterman, D; Cristea, Mc; Yu, H; Rutherford, Tj; Weitzel, Jn; Neuhausen, Sl; Schwartz, Pe; Slack, Fj; Santin, Ad; Weidhaas, J. B.